Page 123 - FINAL PROGRAMME 2017

TUESDAY, 4 JULY 2017
SELECTED ORAL COMMUNICATIONS
15:15 - 16:30 Plenary 2
Session 47: What is new in AMH?
Chairman: J.S. Tapanainen (Finland) Chairman: T. Gürgan (Turkey)
15:15
O-166 Intercyclic variation in AMH levels; challenges of using single-sample measurements for clinical predictions
L. Bungum1, J. Tagevi2, N. Tørring3, C.Y. Andersen4, N. Macklon5, M. Bungum6, A. Giwercman6, S. Skouby7
1Skåne University Hospital Malmö, Reproduktionsmedicinsk Center/FertilitetscentrumIngång 71- Plan 6, Malmö, Sweden
2Skåne University Hospital- Sweden, Reproductive Madicine Center, Malmø, Sweden
3Aarhus University Hospital, Clinical Biology, Aarhus, Denmark
4University Hospital of Copenhagen, Laboratory of Reproductive Biology, Copenhagen, Denmark 5University of Copenhagen and Southampton, Sjælland University Hospital, Roskilde, Denmark 6Skåne University Hospital, Reproductive Medicine Center, Malmø, Sweden
7University of Copenhagen Hospital, Gynecology and Obstetrics, Copenhagen, Denmark
O-167 High AMH in ovulatory women predicts high cumulative pregnancy rate after spontaneous conception
A.S. Korsholm1, K. Birch Petersen1, J.G. Bentzen1, L.M. Hilsted2, A. Nyboe Andersen1, H.W. Hvidman1 1Rigshospitalet, The Fertility Clinic, Copenhagen Ø, Denmark
2Rigshospitalet, Department of Clinical Biochemistry, Copenhagen Ø, Denmark
O-168 The impact of serum anti-Müllerian hormone (AMH) levels on clinical outcome of individualised follitropin delta dosing and conventional follitropin alfa dosing in controlled ovarian stimulation
A. La Marca1, S. Nelson2, M. Göthberg3, B. Mannaerts4, J.C. Arce5, ESTHER-16
1University of Modena and Reggio Emilia and Clinica Eugin, Mother-Infant Department, Modena, Italy
2School of Medicine, University of Glasgow, Glasgow, United Kingdom
3Ferring Pharmaceuticals, Global Clinical R&D- Biometrics, Copenhagen, Denmark
4Ferring Pharmaceuticals, Science and Medicine Reproductive Health, Copenhagen, Denmark
5Ferring Pharmaceuticals, US Development, Parsippany, U.S.A.
6On behalf of the ESTHER-1 trial group, Evidence-based Stimulation Trial with Human rFSH in Europe and Rest of World, Copenhagen, Denmark
15:30
15:45
FINAL PROGRAMME I GENEVA, SWITZERLAND – 2 TO 5 JULY 2017 123
SCIENTIFIC PROGRAMME TUESDAY, 4 JULY